LMS-04: Doxorubicin alone versus doxorubicin with trabectedin for metastatic or unresectable leiomyosarcoma
The combination of doxorubicin and trabectedin significantly improves progression-free survival compared to doxorubicin alone for the first-line treatment of metastatic or unresectable leiomyosarcoma, with an acceptable safety profile despite increased toxicity.